Literature DB >> 7697519

Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.

P K Holder1, S E Maslanka, L B Pais, J Dykes, B D Plikaytis, G M Carlone.   

Abstract

A new standard meningococcal reference serum designated CDC1992 was prepared to replace meningococcal reference sera ECG and PB-2, which are not available in sufficient quantities for continued use as primary reference sera. CDC1992 was prepared from 14 healthy adult volunteers who underwent plasmapheresis 4 to 12 weeks postvaccination with a single dose of a Neisseria meningitidis quadrivalent polysaccharide vaccine. Total and/or class-specific meningococcal serogroup A and C anticapsular antibody concentrations (in micrograms per milliliter) were assigned to CDC1992 by using homologous and heterologous enzyme-linked immunosorbent assay (ELISA) formats. The reference serum ECG was used as a reference standard to assign total anticapsular antibody concentrations to CDC1992 by a homologous ELISA format. A heterologous ELISA format, with the Haemophilus influenzae type b standard reference serum FDA 1983, was used to assign total and class-specific antibody concentrations to CDC1992. Alkaline phosphatase-labeled mouse anti-human monoclonal antibody conjugates were used as secondary antibodies in both ELISA formats. The total, immunoglobulin G (IgG), IgA, and IgM antibody concentrations, assigned to CDC1992 for serogroup A were 135.8, 91.8, 20.1, and 23.9 micrograms/ml, respectively, and those for serogroup C were 32.0, 24.1, 5.9, and 2.0 micrograms/ml, respectively. Meningococcal serogroup A and C antibody concentrations were in good agreement when homologous and heterologous ELISA format results were compared. Total and class-specific serogroup A and C antibody concentrations were determined in six adult quality control serum samples from the Centers for Disease Control and Prevention by using the homologous ELISA and our assigned antibody concentrations for CDC1992. Antibody concentrations in reference sera ECG and PB-2 were measured in order to provide a historical link to previous studies. The general acceptance of CDC1992 as the standard reference serum and the assigned antibody concentrations will allow investigators to compare antibody levels in serum to those in a single reference preparation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697519      PMCID: PMC170115          DOI: 10.1128/cdli.2.2.132-137.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  34 in total

1.  Present status of polysaccharide vaccines in the prevention of meningococcal disease.

Authors:  R Gold; M L Lepow
Journal:  Adv Pediatr       Date:  1976

2.  A fractionating column for analysis of nucleic acids.

Authors:  J D MANDELL; A D HERSHEY
Journal:  Anal Biochem       Date:  1960-06       Impact factor: 3.365

3.  Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies.

Authors:  J B Robbins; J C Parke; R Schneerson; J K Whisnant
Journal:  Pediatr Res       Date:  1973-03       Impact factor: 3.756

4.  Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.

Authors:  P H Mäkelä; H Peltola; H Käyhty; H Jousimies; O Pettay; E Ruoslahti; A Sivonen; O V Renkonen
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

5.  Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.

Authors:  R Gold; M L Lepow; I Goldschneider; T F Draper; E C Gotshlich
Journal:  J Infect Dis       Date:  1979-11       Impact factor: 5.226

6.  Immunogenicity of group A and group C meningococcal polysaccharides in human infants.

Authors:  I Goldschneider; M L Lepow; E C Gotschlich; F T Mauck; F Bachl; M Randolph
Journal:  J Infect Dis       Date:  1973-12       Impact factor: 5.226

7.  Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines.

Authors:  M L Lepow; I Goldschneider; R Gold; M Randolph; E C Gotschlich
Journal:  Pediatrics       Date:  1977-11       Impact factor: 7.124

8.  Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.

Authors:  H Käyhty; V Karanko; H Peltola; S Sarna; P H Mäkelä
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

9.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  37 in total

1.  Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y, and W-135 meningococcal standard reference serum CDC1992.

Authors:  Cheryl M Elie; Patricia K Holder; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients.

Authors:  A Meerveld-Eggink; O de Weerdt; R M de Voer; G A M Berbers; H van Velzen-Blad; B J Vlaminckx; D H Biesma; G T Rijkers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-24       Impact factor: 3.267

3.  Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients.

Authors:  M Drogari-Apiranthitou; C A Fijen; D Van De Beek; E F Hensen; J Dankert; E J Kuijper
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

4.  Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Authors:  Peter C Giardina; Emma Longworth; Renee E Evans-Johnson; Michaelene L Bessette; Hong Zhang; Ray Borrow; Dace Madore; Philip Fernsten
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

5.  Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine.

Authors:  Helen Findlow; Jo Southern; Lesley Mabey; Paul Balmer; Robert S Heyderman; Cressida Auckland; Rhonwen Morris; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2006-04

6.  Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy.

Authors:  T J O'Dempsey; T McArdle; S J Ceesay; O Secka; E Demba; W A Banya; N Francis; B M Greenwood
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-01       Impact factor: 5.747

7.  Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

Authors:  Caroline L Trotter; Ray Borrow; Jamie Findlow; Ann Holland; Sarah Frankland; Nick J Andrews; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

8.  Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides.

Authors:  Richarda M de Voer; Fiona R M van der Klis; Carla W A M Engels; Ger T Rijkers; Elisabeth A Sanders; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2008-06-11

9.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

10.  A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.

Authors:  Shousun C Szu; Steven Hunt; Guilin Xie; John B Robbins; Rachel Schneerson; Rajesh K Gupta; Zhigang Zhao; Xiaomei Tan
Journal:  Vaccine       Date:  2013-02-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.